Rein Therapeutics, Inc. · NASDAQ:RNTX
BIOS CAPITAL MANAGEMENT, LP reported a 9.99% stake in Rein Therapeutics, Inc. (Schedule 13G/A)
Event May 6, 2026 · Filed May 8, 2026
BIOS CAPITAL MANAGEMENT, LP reported a 9.99% stake in Rein Therapeutics, Inc., 7,797,502 shares, as a passive investor on May 6, 2026. Filed May 8, 2026 (Schedule 13G/A).
- Stake
- 9.99%
- Shares
- 7,797,502
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 24 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Bios Fund I, LP | 2.06% | 1,610,565 |
| BIOS CAPITAL MANAGEMENT, LP | 9.99% | 7,797,502 |
| BIOS FUND II, LP | 0.51% | 398,767 |
| BIOS FUND II QP, LP | 1.67% | 1,302,654 |
| BIOS FUND II NT, LP | 0.22% | 173,217 |
| BIOS EQUITY PARTNERS, LP | 0% | 1,249 |
| BIOS CLINICAL OPPORTUNITY FUND, LP | 2.96% | 2,313,797 |
| BIOS FUND III QP, LP | 1.71% | 1,332,850 |
| BIOS FUND III NT, LP | 0.27% | 214,346 |
| BIOS ADVISORS GP, LLC | 9.99% | 7,797,502 |
| BIOS FUND III, LP | 0.26% | 204,092 |
| BIOS EQUITY COF, LP | 2.24% | 1,751,288 |
| BIOS EQUITY PARTNERS II, LP | 2.40% | 1,874,638 |
| BIOS EQUITY PARTNERS III, LP | 2.24% | 1,751,288 |
| CAVU ADVISORS, LLC | 9.99% | 7,797,502 |
| CAVU MANAGEMENT, LP | 9.99% | 7,797,502 |
| LESLIE W. KREIS | 9.99% | 7,797,502 |
| AARON G.L. FLETCHER | 9.99% | 7,797,502 |
| BIOS FUND I QP, LP | 1.21% | 941,887 |
| Bios LTI Co-Invest III QP, LP | 5.51% | 4,303,099 |
| Bios LTI Co-Invest III, LP | 5.38% | 4,198,037 |
| Bios LTI SPV II, LP | 1.91% | 1,487,007 |
| Bios 2026 Co-Invest, LP | 1.28% | 1,000,000 |
| Bios 2024 Co-Invest, LP | 0.72% | 562,695 |
Source
Related
- Rein Therapeutics, Inc.
- BIOS Fund I, LP
- Rein Therapeutics, Inc. shareholders
- Schedule 13G/A · Lynwood Capital Management Inc. · Aug 14, 2026
- Schedule 13G · ADAR1 Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Laurence W. Lytton · Aug 13, 2026
- Schedule 13G/A · Voss Capital, LP · Jul 14, 2026
- Form 4 · Von Rickenbach Josef H · May 28, 2026